Added to YB: 2026-06-15
Pitch date: 2026-06-10
ARQT [neutral]
Arcutis Biotherapeutics, Inc.
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
Market Cap
$3.0B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
467.59
P/E
-1.3K
EV/Sales
7.07
Sector
Biotechnology
Category
growth
Show full summary:
GS Healthcare Conference – Recap (Day 2 – Part 2) - Arcutis Biotherapeutics, Inc.
ARQT (overview): Derm platform around ZORYVE, early in lifecycle w/ $3B+ peak sales potential. Already cash-flow positive, self-funding. Catalysts: June 29 pediatric psoriasis PDUFA, atopic dermatitis filing (PDUFA early '27), vitiligo & HS Ph2 data. Medicare access ~30M lives. M&A Score 71, Growth 77.
Read full article (1 min)